Among the following medications—atorvastatin, baclofen, cetirizine (Zyrtec), citalopram, finasteride, hydrochlorothiazide, metformin, nadolol, sildenafil (Viagra), and ursodiol—which are known to cause prolonged QT interval?

QT-Prolonging Medications from Your List

Among the medications listed, citalopram is the primary drug known to cause clinically significant QT interval prolongation, while hydrochlorothiazide can indirectly contribute through electrolyte disturbances.

Direct QT-Prolonging Medications

Citalopram (High Risk)

Citalopram causes dose-dependent QTc prolongation and carries the highest risk among your listed medications 111. The FDA label explicitly warns that:

• At 20 mg: QTc increases by 8.5 ms (upper CI: 10.8 ms)
• At 40 mg: QTc increases by 12.6 ms (upper CI: 14.3 ms)
• At 60 mg: QTc increases by 18.5 ms (upper CI: 21.0 ms)

The 2023 Canadian Cardiovascular Society guidelines specifically identify citalopram as having the highest risk among SSRI antidepressants for causing arrhythmias 222. Real-world pharmacovigilance data confirms citalopram as one of the top three drugs causing QT prolongation (720 cases, ROR = 13.63) 3.

Key FDA restrictions for citalopram 1:

• Maximum dose: 40 mg/day (20 mg/day if age >60 years, hepatic impairment, or CYP2C19 poor metabolizers)
• Contraindicated in congenital long QT syndrome, recent MI, uncompensated heart failure
• Should not be combined with other QT-prolonging drugs
• Discontinue if QTc >500 ms

Indirect Contributors

Hydrochlorothiazide (Moderate Risk via Electrolyte Depletion)

While hydrochlorothiazide does not directly prolong the QT interval, it significantly increases risk through hypokalemia and hypomagnesemia 222. The 2023 guidelines explicitly warn: "when a diuretic is used with sotalol, be mindful of the potential for hypokalemia and hypomagnesemia" 2. This same principle applies to any QT-prolonging medication.

A case series documented multifactorial QT prolongation where hydrochlorothiazide-induced hypokalemia contributed to torsades de pointes in a patient taking citalopram 4. Studies in CKD patients found diuretics associated with QT changes, though effects were partially mediated through electrolyte disturbances 5.

Cetirizine/Zyrtec (Minimal to No Risk)

Cetirizine is a second-generation antihistamine with negligible QT-prolonging effects. Unlike first-generation antihistamines (terfenadine, astemizole) that were withdrawn from the market, cetirizine does not significantly block cardiac potassium channels 6.

Medications Without Significant QT Risk

The following medications from your list are not associated with clinically meaningful QT prolongation:

• Atorvastatin: No QT effects documented
• Baclofen: No cardiac conduction effects
• Finasteride: No QT prolongation reported
• Metformin: No QT effects; actually used safely in the study populations 5
• Nadolol: Beta-blocker; may actually shorten QT interval and is protective in congenital LQTS 2
• Sildenafil (Viagra): No significant QT prolongation at therapeutic doses
• Ursodiol: No cardiac conduction effects

Clinical Risk Stratification

High-risk scenario requiring ECG monitoring 22:

• Patient taking citalopram (especially >20 mg/day)
• Concurrent hydrochlorothiazide use
• Additional risk factors: age >60, female sex, structural heart disease, baseline QTc >450 ms

Risk mitigation strategies 22:

1. Check baseline ECG before starting citalopram if electrolyte disturbances present or patient on diuretics
2. Monitor potassium and magnesium levels regularly when combining citalopram with hydrochlorothiazide
3. Correct hypokalemia to >4.0 mEq/L and hypomagnesemia before initiating QT-prolonging drugs
4. Consider alternative SSRI (sertraline, paroxetine have negligible QT effects) 22
5. Discontinue citalopram if QTc exceeds 500 ms or increases >60-70 ms from baseline 2

Common Pitfall

The most dangerous scenario is combining citalopram with hydrochlorothiazide without monitoring electrolytes. The diuretic-induced hypokalemia amplifies citalopram's QT-prolonging effect, creating a synergistic risk for torsades de pointes 4. This combination requires vigilant electrolyte monitoring and consideration of potassium supplementation.